New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi‐Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center

[1]  A. Gown,et al.  Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. , 2018, Archives of pathology & laboratory medicine.

[2]  M. Zauderer,et al.  Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1 , 2017, Oncotarget.

[3]  A. Churg,et al.  GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung , 2017, The American journal of surgical pathology.

[4]  F. Galateau-Sallé,et al.  The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. , 2017, Human pathology.

[5]  N. Le Stang,et al.  PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better? , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  J. Vergnon,et al.  Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies , 2017, Virchows Archiv.

[7]  M. Tagawa,et al.  Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma. , 2017, Annals of diagnostic pathology.

[8]  N. Le Stang,et al.  Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. , 2016, Human pathology.

[9]  A. Gown,et al.  BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas , 2016, The American journal of surgical pathology.

[10]  Olivier Molinier,et al.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.

[11]  F. Galateau-Sallé,et al.  New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet? , 2016, Archives of pathology & laboratory medicine.

[12]  F. Galateau-Sallé,et al.  Dataset for Reporting of Malignant Mesothelioma of the Pleura or Peritoneum: Recommendations From the International Collaboration on Cancer Reporting (ICCR). , 2016, Archives of pathology & laboratory medicine.

[13]  Thomas D. Wu,et al.  Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations , 2016, Nature Genetics.

[14]  F. Galateau-Sallé,et al.  The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  K. Nackaerts,et al.  Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. , 2015, The Lancet. Oncology.

[16]  T. Yamanaka,et al.  Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial) , 2015, International Journal of Clinical Oncology.

[17]  A. Husain,et al.  BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma. , 2015, Human pathology.

[18]  B. Seifert,et al.  A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years’ Experience , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  G. Rossi,et al.  BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations , 2015, Modern Pathology.

[20]  A. Gown,et al.  BAP1 Immunohistochemistry and p16 FISH to Separate Benign From Malignant Mesothelial Proliferations , 2015, The American journal of surgical pathology.

[21]  S. Patz,et al.  Novel MR Imaging Applications for Pleural evaluation. , 2015, Magnetic resonance imaging clinics of North America.

[22]  W. Travis.  WHO classification of tumours of the lung, pleura, thymus and heart , 2015 .

[23]  A. Sahin,et al.  Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study. , 2014, Human pathology.

[24]  L. Chirieac,et al.  p16 Deletion in sarcomatoid tumors of the lung and pleura. , 2013, Archives of pathology & laboratory medicine.

[25]  C. Sima,et al.  High SUVmax on FDG-PET Indicates Pleomorphic Subtype in Epithelioid Malignant Pleural Mesothelioma: Supportive Evidence to Reclassify Pleomorphic as Nonepithelioid Histology , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  C. Sima,et al.  A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma , 2012, Modern Pathology.

[27]  F. Galateau-Sallé,et al.  The Separation of Benign and Malignant Mesothelial Proliferations , 2000, Archives of pathology & laboratory medicine.

[28]  R. Kelly,et al.  Chemotherapy and targeted therapies for unresectable malignant mesothelioma. , 2011, Lung cancer.

[29]  Liang Cheng,et al.  Expression of PAX8 in Normal and Neoplastic Tissues: A Comprehensive Immunohistochemical Study , 2011, Applied immunohistochemistry & molecular morphology : AIMM.

[30]  C. Sima,et al.  Pleomorphic Epithelioid Diffuse Malignant Pleural Mesothelioma: A Clinicopathological Review and Conceptual Proposal to Reclassify as Biphasic or Sarcomatoid Mesothelioma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  R. Gill.  Imaging of mesothelioma. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[32]  V. Roggli,et al.  Sarcomatoid mesothelioma: a clinical–pathologic correlation of 326 cases , 2010, Modern Pathology.

[33]  Y. Takeshima,et al.  Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma , 2009, Histopathology.

[34]  K. Nackaerts,et al.  Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[35]  D. Henderson,et al.  Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review , 2008, Modern Pathology.

[36]  Y. Takeshima,et al.  Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry , 2008, Pathology international.

[37]  J. Ronan,et al.  Expression of mesothelial markers in malignant mesotheliomas: an immunohistochemical evaluation of 173 cases. , 2005, JPMA. The Journal of the Pakistan Medical Association.

[38]  H. Pass,et al.  Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study , 2003, Histopathology.

[39]  R. Attanoos,et al.  Anti‐mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms , 2000, Histopathology.

[40]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.